129 related articles for article (PubMed ID: 8785705)
1. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector.
Toloza EM; Hunt K; Swisher S; McBride W; Lau R; Pang S; Rhoades K; Drake T; Belldegrun A; Glaspy J; Economou JS
Cancer Gene Ther; 1996; 3(1):11-7. PubMed ID: 8785705
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated suicide gene therapy for experimental bladder cancer.
Sutton MA; Berkman SA; Chen SH; Block A; Dang TD; Kattan MW; Wheeler TM; Rowley DR; Woo SL; Lerner SP
Urology; 1997 Feb; 49(2):173-80. PubMed ID: 9037277
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection.
Yao X; Yoshioka Y; Eto Y; Morishige T; Okada Y; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
Biochem Biophys Res Commun; 2007 Oct; 362(2):419-24. PubMed ID: 17707336
[TBL] [Abstract][Full Text] [Related]
4. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.
Tjuvajev JG; Chen SH; Joshi A; Joshi R; Guo ZS; Balatoni J; Ballon D; Koutcher J; Finn R; Woo SL; Blasberg RG
Cancer Res; 1999 Oct; 59(20):5186-93. PubMed ID: 10537296
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
6. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity.
Gu J; Andreeff M; Roth JA; Fang B
Gene Ther; 2002 Jan; 9(1):30-7. PubMed ID: 11850720
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter.
Freund CT; Tong XW; Block A; Contant CF; Kieback DG; Rowley DR; Lerner SP
Anticancer Res; 2000; 20(5A):2811-6. PubMed ID: 11062688
[TBL] [Abstract][Full Text] [Related]
9. In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer.
Sutton MA; Freund CT; Berkman SA; Dang TD; Kattan MW; Wheeler TM; Rowley DR; Lerner SP
Mol Ther; 2000 Sep; 2(3):211-7. PubMed ID: 10985951
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo.
Huang H; Chen SH; Kosai K; Finegold MJ; Woo SL
Gene Ther; 1996 Nov; 3(11):980-7. PubMed ID: 8940638
[TBL] [Abstract][Full Text] [Related]
11. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta.
Peplinski GR; Tsung AK; Casey MJ; Meko JB; Fredrickson TN; Buller RM; Norton JA
Cancer J Sci Am; 1996; 2(1):21-7. PubMed ID: 9166494
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
13. Use of protamine to augment adenovirus-mediated cancer gene therapy.
Lanuti M; Kouri CE; Force S; Chang M; Amin K; Xu K; Blair I; Kaiser L; Albelda S
Gene Ther; 1999 Sep; 6(9):1600-10. PubMed ID: 10490770
[TBL] [Abstract][Full Text] [Related]
14. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
Anderson LM; Swaminathan S; Zackon I; Tajuddin AK; Thimmapaya B; Weitzman SA
Gene Ther; 1999 May; 6(5):854-64. PubMed ID: 10505111
[TBL] [Abstract][Full Text] [Related]
16. Gene delivery into malignant cells in vivo by a conjugated adenovirus/DNA complex.
Nguyen DM; Wiehle SA; Roth JA; Cristiano RJ
Cancer Gene Ther; 1997; 4(3):183-90. PubMed ID: 9171937
[TBL] [Abstract][Full Text] [Related]
17. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex.
Nguyen DM; Wiehle SA; Koch PE; Branch C; Yen N; Roth JA; Cristiano RJ
Cancer Gene Ther; 1997; 4(3):191-8. PubMed ID: 9171938
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
Wright P; Zheng C; Moyana T; Xiang J
Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
[TBL] [Abstract][Full Text] [Related]
19. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific transcriptional targeting of suicide gene therapy.
Qiao J; Doubrovin M; Sauter BV; Huang Y; Guo ZS; Balatoni J; Akhurst T; Blasberg RG; Tjuvajev JG; Chen SH; Woo SL
Gene Ther; 2002 Feb; 9(3):168-75. PubMed ID: 11859419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
